Ginkgo Bioworks Holdings (DNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE
Market Cap: $622.97M
Last updated: Nov 17, 2026 at 4:37 PM ET
Ginkgo Bioworks Holdings (DNA) Statistics
Ginkgo Bioworks Holdings (DNA) has a market cap of $622.97M and an enterprise value of $538.46M. It kept -249.20% of revenue as net income over the last 12 months. Its share count is up 14.98% from a year earlier.
Total Valuation
Enterprise value is 13.56% below the market cap, as cash exceeds debt.
| Market Cap | $622.97M |
|---|---|
| Enterprise Value | $538.46M |
| Latest price (Nov 17, 2026) | $8.31 |
Key Dates
| Last Earnings Date | Nov 5, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.3x and 1.4x. Its year-end P/S ranged from 2.2x to 13.0x from 2022 to 2025.
| P/S Ratio | 5.3x |
|---|---|
| Forward P/S | 6.9x |
| P/B Ratio | 1.4x |
| P/TBV Ratio | 1.5x |
Price Statistics
The stock is up 3.55% over 52 weeks and trades 19.71% below its 50-day average.
| Beta (1Y) | 3.31 |
|---|---|
| 52-Week Change | +3.55% |
| 1-Month Change | -17.43% |
| 3-Month Change | +7.85% |
| 6-Month Change | +12.98% |
| 5-Year Change | -97.97% |
| Total Return (1Y) | +3.55% |
| Total Return (3Y CAGR) | -48.47% |
| Total Return (5Y CAGR) | -55.57% |
| Return vs SPY (1Y) | -5.36% |
| Max Drawdown (1Y) | -48.79% |
| Max Drawdown (3Y) | -92.51% |
| Sharpe Ratio (1Y) | 0.06 |
| Correlation with SPY (1Y) | 0.43 |
| 50-Day Average | $10.35 |
| 200-Day Average | $8.63 |
| 52-Week Range | $5.37 to $18.22 |
| RSI (14 Days) | 40.0 |
| Average Volume (20 Days) | 2.52M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.72x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.72x |
|---|---|
| Quick Ratio | 4.72x |
| Debt / Equity | 0.00x |
| Interest Coverage | -30.36x |
Returns and Efficiency
Return on equity is -63.93% over the last 12 months, against a 5-year average of -92.52%.
| Return on Equity (ROE) | -63.93% |
|---|---|
| Return on Assets (ROA) | -26.58% |
| Return on Capital Employed (ROCE) | -27.70% |
| ROE (5Y Average) | -92.52% |
| ROA (5Y Average) | -58.58% |
| ROIC (5Y Average) | -62.71% |
| Asset Turnover | 0.09x |
| Receivables Turnover | 8.22x |
Scores
DNA has an Altman Z-Score of -9.22, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -9.22 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $100.74M over the last 12 months is down 33.11% from the 12 months before.
| Revenue | $100.74M |
|---|---|
| Revenue Growth (YoY) | -33.11% |
| Gross Profit | $102.62M |
| Operating Income | -$239.49M |
| Pretax Income | -$255.98M |
| Net Income | -$251.03M |
| EBITDA | -$192.58M |
| EBIT | -$243.40M |
| Reported EPS (TTM) | -$4.31 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 41.57% of the $944.45M in total assets.
| Cash and Equivalents | $84.50M |
|---|---|
| Total Debt | $0 |
| Net Cash | $84.50M |
| Net Cash Per Share | $1.32 |
| Working Capital | $244.99M |
| Shareholder Equity | $392.64M |
| Book Value Per Share | $6.14 |
| Tangible Book Value | $352.91M |
| Tangible Book Per Share | $5.52 |
| Total Assets | $944.45M |
| Total Liabilities | $551.82M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $6.56M of capital spending, operating cash flow left -$173.54M of free cash flow.
| Operating Cash Flow | -$166.99M |
|---|---|
| Capital Expenditures | $6.56M |
| Free Cash Flow | -$173.54M |
| FCF Per Share | -$3.13 |
| Depreciation and Amortization | $50.81M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -237.74%.
| Gross Margin | 101.87% |
|---|---|
| Operating Margin | -237.74% |
| Pretax Margin | -254.11% |
| Net Margin | -249.20% |
| EBITDA Margin | -191.17% |
| EBIT Margin | -241.62% |
| FCF Margin | -172.27% |
| Gross Margin (5Y Average) | 69.44% |
Growth
Revenue fell 29.11% a year over 3 years.
| Revenue Growth (3Y CAGR) | -29.11% |
|---|---|
| Revenue Growth (5Y CAGR) | +17.29% |
| Book Value Per Share Growth (2Y CAGR) | -35.33% |
| Tangible Book Per Share Growth (2Y CAGR) | -34.78% |
Dividends and Yields
DNA does not pay a dividend. Its free cash flow yield is -32.63%.
| FCF Yield | -32.63% |
|---|---|
| Buyback Yield | -2.76% |
| Shareholder Yield | -2.76% |
Stock Splits
The last split was a 1-for-40 reverse split on Aug 20, 2024.
| Last Split Date | Aug 20, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:40 |
Peer Position
Against 6 similar companies, DNA has the 4th highest P/S.
P/S RatioPeer median 9.2x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +1.89%
| P/S Ratio | 5.3x vs 9.2x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -33.11% vs +1.89% median |
Analyst Forecast
Consensus estimates put revenue growth at -24.54% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -24.54% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About DNA
What is DNA's market cap?
Ginkgo Bioworks Holdings has a market cap of $622.97M. Its enterprise value, which adds debt and subtracts cash, is $538.46M.
How many shares of DNA are outstanding?
Ginkgo Bioworks Holdings has 63.97M shares outstanding. The count is up 14.98% from a year earlier.
Does DNA pay a dividend?
No. Ginkgo Bioworks Holdings does not pay a dividend.
How much debt does DNA have?
Ginkgo Bioworks Holdings has $0 of total debt and $84.50M of cash and equivalents, a net cash position of $84.50M.
DNA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts